AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. ・Shares have strong technical momentum and a 100 ...

AnaptysBio, Inc. receives a "Hold" rating for its U.S.-listed shares. It shows a 16.42% increase in stock market value since the last "Buy" rating. AnaptysBio's immunotherapy portfolio includes ...

US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and take advantage of attractive levels. AnaptysBio, Inc.

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Research analysts at HC Wainwright dropped their Q3 2025 earnings estimates for shares of AnaptysBio in a research report issued on Tuesday, September ...

AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $1.06 per share. This compares to a loss of $1.14 per share a year ago.

AnaptysBio (NASDAQ: ANAB) checks many boxes that make it an attractive biotech investment: It's got a sizable cash position, reputable pharma partners, and a promising drug pipeline. Throw in a ...

Shares of clinical-stage biotech AnaptysBio (NASDAQ: ANAB) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% as of 12:58 p.m.

There was some encouraging news from across the Atlantic. GlaxoSmithKline, a global pharmaceutical company, has partnered with immunotherapy specialist AnaptysBio on that drug and several other ...

AnaptysBio had $428.5 million in cash and equivalents on its books at the end of 2019, providing ample resources for its research and development activities. The company expects a net cash burn of $60 ...